Show simple item record

dc.contributor.authorSantos García, Diego
dc.contributor.authorEscamilla Sevilla, Francisco
dc.date.accessioned2021-11-10T11:19:32Z
dc.date.available2021-11-10T11:19:32Z
dc.date.issued2021-08
dc.identifier.citationSantos García, D.; Blázquez-Estrada, M.; Calopa, M.; Escamilla-Sevilla, F.; Freire, E.; García Ruiz, P.J.; Grandas, F.; Kulisevsky, J.; López-Manzanares, L.; Martínez Castrillo, J.C.; et al. Present and Future of Parkinson’s Disease in Spain: PARKINSON-2030 Delphi Project. Brain Sci. 2021, 11, 1027. [https://doi.org/10.3390/brainsci11081]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/71413
dc.descriptionThis project was funded by Zambon S.A.U.es_ES
dc.descriptionD.S.G., M.B.-E., J.K., F.P.-E., F.V., M.-R.L. and J.P. declare no conflict of interest. M.C. has received honoraria for lecturing or advisory boards from AbbVie, Bial and Zambon. F.E.-S. has received honoraria as a speaker, support to attend scientific meetings and grants for conducting studies from Abbvie, Bial, Boston Scientifice, Medtronic, Merz Pharma, Teva, UCB Pharma and Zambon. E.F. has received advisory, consulting and lectures fees from Abbvie, Teva, Bial, Zambon and Neuraxpharm. For P.J.G.R., no specific funding was received for this study. The author reports no conflicts of interest. In the previous 12 months, this author received research support from Aller gan and UCB, personal compensation as a consultant/scientific advisory boards from Italfarmaco, Britannia, Bial and Zambon and speaking honoraria from Italfarmaco, Zambon, Allergan and Abbvie. F.G. received grants from the Instituto de Salud Carlos III and from the European Commission (Horizon 2020). He received consulting honoraria from Exeltis and for lecturing from Zambon and TEVA. L.L.-M. has received compensated advisory services, consulting, research grant support, or speaker honoraria from AbbVie, Acorda, Bial, Intec Pharma, Italfarmaco, Pfizer, Roche, Teva, UCB and Zambon. J.C.M.C. has received honoraria as a speaker from Abbvie, Allergan, Bial, Boehringer Ingelheim, GSK, Krka Farmaceutica, Merz Pharma, Ipsen, Italfarmaco, Lundbeck, Medtronic, TEVA, UCB and Zambon; research grants from Abbvie, Allergan, Merz Pharma, Italfarmaco, Lundbeck, UCB and Zambon; and participated in the advisory boards of Abbvie, Allergan, GSK, Bial, Merz Pharma, Merck, Boehringer Ingelheim, Ipsen, Italfarmaco, Lundbeck, Orion, UCB and Zambon. P.M. has received support for attending meetings and/or honorarium for lecturing from Abbott, Allergan, Abbvie, Bial, Britannia, Italfarmaco, Merz, UCB, Roche, Teva and Zambon. J.M.S. has participated in advisory boards and pharmaceutical industry-sponsored symposia for Zambon, UCB, Bial, Italfarmaco, Eisai España and Abbvie Spain. B.T.: speaking fees, AbbVie, and travel expenses, Italfarmaco. R.Y. has received honoraria as a speaker for Bial, Italfarmaco, Teva and Zambon, support to attend scientific meetings from Alter, for consultancy from Bial, and sponsored for conducting studies from Zambon and Lundbeck. A.A. is employed and receives personal fees from Zambon.es_ES
dc.description.abstractParkinson's disease (PD) is a chronic progressive and irreversible disease and the second most common neurodegenerative disease worldwide. In Spain, it affects around 120.000-150.000 individuals, and its prevalence is estimated to increase in the future. PD has a great impact on patients' and caregivers' lives and also entails a substantial socioeconomic burden. The aim of the present study was to examine the current situation and the 10-year PD forecast for Spain in order to optimize and design future management strategies. This study was performed using the modified Delphi method to try to obtain a consensus among a panel of movement disorders experts. According to the panel, future PD management will improve diagnostic capacity and follow-up, it will include multidisciplinary teams, and innovative treatments will be developed. The expansion of new technologies and studies on biomarkers will have an impact on future PD management, leading to more accurate diagnoses, prognoses, and individualized therapies. However, the socio-economic impact of the disease will continue to be significant by 2030, especially for patients in advanced stages. This study highlighted the unmet needs in diagnosis and treatment and how crucial it is to establish recommendations for future diagnostic and therapeutic management of PD.es_ES
dc.description.sponsorshipPfizeres_ES
dc.description.sponsorshipRochees_ES
dc.description.sponsorshipTeva Pharmaceutical Industrieses_ES
dc.description.sponsorshipUCBes_ES
dc.description.sponsorshipEuropean Commissiones_ES
dc.description.sponsorshipInstituto de Salud Carlos IIIes_ES
dc.description.sponsorshipHorizon 2020es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectDiagnosises_ES
dc.subjectEconomic impactes_ES
dc.subjectEpidemiology es_ES
dc.subjectManagementes_ES
dc.subjectMortality es_ES
dc.subjectParkinson’s diseasees_ES
dc.subjectQuality of lifees_ES
dc.subjectSpaines_ES
dc.subjectTreatment es_ES
dc.titlePresent and Future of Parkinson's Disease in Spain: PARKINSON-2030 Delphi Projectes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/brainsci11081027
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España